Microscopic polyangiitis

Synonyms
microscopic polyarteritis, MPA, p-ANCA vasculitis, MPO-ANCA, pulmonary-renal syndrome
Specialty
Internal medicine · Rheumatology & immunology
Images
Histology 1 · Blood smear & cytology 1
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Aetiopathogenesis
  5. Clinical features
  6. Diagnosis
  7. Treatment principles
  8. Keep learning in the app
  9. Further reading (open access)
  10. Cross-references

Images (2)

Microscopic polyangiitis – histology: Renal biopsy in ANCA-associated glomerulonephritis: fibrinoid necrosis in a glomerulus, eosinophilic on H&E (left) and red on trichrome (right, arrows)Histology
Renal biopsy in ANCA-associated glomerulonephritis: fibrinoid necrosis in a glomerulus, eosinophilic on H&E (left) and red on trichrome (right, arrows)Image: Angela Xue, Adele Bernard, Vanessa Moreno, Lindsey Phillips, Evan Raff (Wikimedia Commons) · CC BY 4.0 · Source
Microscopic polyangiitis – Indirect immunofluorescence on ethanol-fixed neutrophils: perinuclear pattern (p-ANCA) caused by MPO antibodiesBlood smear & cytology
Indirect immunofluorescence on ethanol-fixed neutrophils: perinuclear pattern (p-ANCA) caused by MPO antibodiesImage: Simon Caulton, “P ANCA” (Wikimedia Commons) · CC BY-SA 3.0 · Source
1 / 2

Definition

Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis mainly of small vessels without immunoglobulin deposition (pauci-immune). It may begin as a pulmonary-renal syndrome with rapidly progressive glomerulonephritis and alveolar hemorrhage; the pattern depends on the organs affected. Unlike GPA, granulomas are absent.

Classification

In the 2012 Chapel Hill nomenclature, MPA belongs to the ANCA-associated small-vessel vasculitides. Among the features of the 2022 ACR/EULAR classification criteria, MPO or p-ANCA and pauci-immune glomerulonephritis are the most frequent in MPA; pulmonary fibrosis or interstitial lung disease are also included.

Aetiopathogenesis

It is an autoimmune disease; at least 70 % of patients have ANCA, usually perinuclear ANCA (p-ANCA) with antibodies against myeloperoxidase (MPO). Vascular inflammation occurs without relevant immune complex deposition.

Clinical features

A prodromal illness with fever, weight loss, myalgia, and arthralgia usually precedes.

  • Kidney (in up to 90 %): hematuria, proteinuria (sometimes above 3 g/24 h), red cell casts; without prompt diagnosis, renal failure may follow rapidly.
  • Skin: purpuric rash in about one-third at diagnosis; nail bed infarcts, splinter hemorrhages.
  • Lung: alveolar hemorrhage with rapid-onset dyspnea and anemia, with or without hemoptysis; later pulmonary fibrosis; sometimes interstitial lung disease as the first manifestation. Mild rhinitis or sinusitis possible.
  • Nervous system: frequently mononeuritis multiplex of peripheral or cranial nerves; rarely cerebral vasculitis.
  • Gastrointestinal: abdominal pain, nausea, vomiting, diarrhea, bloody stools.
  • Rarely the heart; eyes usually as episcleritis.

Diagnosis

  • Suspicion with an unexplained combination of fever, weight loss, arthralgias, abdominal pain, alveolar hemorrhage, new-onset nephritic syndrome, or mononeuritis multiplex.
  • Laboratory tests: ESR, CRP, white cell and platelet counts elevated; anemia of chronic disease; an acute drop in hematocrit indicates alveolar or gastrointestinal hemorrhage. Urinalysis with sediment (hematuria, proteinuria, casts) and creatinine.
  • ANCA by immunofluorescence and ELISA: usually p-ANCA/MPO.
  • Biopsy of the most accessible involved tissue; in the kidney, focal segmental pauci-immune necrotizing glomerulonephritis with fibrinoid necrosis and cellular crescents.
  • Chest imaging: bilateral patchy infiltrates suggest alveolar hemorrhage; CT is much more sensitive than radiographs. Bronchoscopy shows blood from all bronchi and later hemosiderin-laden macrophages and excludes infection.

Treatment principles

  • Induction therapy for organ- or life-threatening disease consists of high-dose glucocorticoids combined with anti-CD20 antibodies or alkylating agents.
  • A C5a receptor inhibitor allows glucocorticoid sparing, and plasma exchange is considered in selected cases such as severe alveolar haemorrhage.
  • Once remission is achieved, longer-term maintenance therapy follows, together with infection prophylaxis and multidisciplinary care.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Microscopic polyangiitis with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. MSD Manual Professional: Microscopic Polyangiitis (MPA)
  2. MSD Manual Professional: Overview of Vasculitis
  3. Performance of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for antineutrophil cytoplasmic antibody-associated vasculitis in previously diagnosed adult patients from Türkiye
  4. A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Rheumatoid arthritis · Systemic lupus erythematosus (SLE) · Granulomatosis with polyangiitis (GPA)

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.